Scribe Therapeutics
Beam Therapeutics
New York University/New York Genome Center
A CRISPR Approach to Genetic Medicine
- Time:
The remarkable rise of CRISPR genome editing technology was highlighted recently with the award of the 2020 Nobel Prize in Chemistry. While this transformational technology has countless applications in basic research, agbiotech, synthetic biology, and many other fields, most attention is currently focused on its clinical potential.
Several biotech companies have launched CRISPR gene editing clinical trials in sickle-cell disease, hereditary blindness, and amyloidosis. A new wave of start-ups is hard on their heels, hoping to apply CRISPR to a longer list of ex vivo and in vivo therapies. Meanwhile, researchers are also applying CRISPR screens to better understand host factors that influence the progression of COVID-19.
On Episode 6 of GEN Live, we’ll discuss with a pair of talented genome editing pioneers how CRISPR and allied technologies are showing promise for the treatment and diagnosis of genetic diseases and providing new clues to combat the COVID-19 pandemic.
Special Guests:
• Benjamin L. Oakes, PhD – Scribe Therapeutics
• Nicole Gaudelli, PhD – Beam Therapeutics
• Neville Sanjana, PhD – New York University/New York Genome Center
GEN hosts:
• John Sterling – GEN Editor-in-Chief
• Julianna LeMieux PhD – GEN Senior Science Editor
• Kevin Davies, PhD – GEN/The CRISPR Journal
Produced with support from:
